Tourette Syndrome Clinical Trials 2024

Tourette Syndrome Clinical Trials 2024

Tourette Syndrome research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in tourette syndrome clinical trials today.

Trials for TS Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to tourette syndrome

What are the top hospitals conducting tourette syndrome research?

Advancements in the understanding and treatment of Tourette syndrome are being made by top hospitals across the United States. In Nashville, Access Clinical Trials, Inc. is actively involved in two clinical trials focused on this complex neurological condition. Since their first recorded trial in 2019, they have contributed to a total of four studies related to Tourette syndrome. Further west in Salt Lake City, the University of Utah has also dedicated their efforts to understanding and managing this disorder. With two ongoing trials and four completed ones since 2010, they continue to make significant strides.

The Yale Child Study Center in New Haven is another prominent institution contributing to advancements in treating Tourette syndrome. Alongside two current clinical trials, they have conducted six previous studies since joining the field back in 2010. Meanwhile, at Johns Hopkins University School of Medicine located in Baltimore, researchers are conducting two active clinical trials for Tourette syndrome as part of their commitment towards improving patient outcomes. They too have been involved with four prior investigations since recording their first trial only recently alongside Access Clinical Trials Inc., namely last year (in 2019).

Lastly but certainly not leastly is Cincinnati Children's Hospital Medical Center situated within Cincinnati where there are currently running tests regarding this matter just like fellow counterparts mentioned above number up until two while collectively they've successfully earlier accomplished three separate experiments; all started upon commencement from around more than ten years ago specifically during early months spanning throughout year twenty-ten.

These esteemed institutions exemplify a shared goal: bettering the lives of individuals affected by Tourette syndrome through rigorous research and innovative treatments. By actively engaging patients and investing resources into clinical trials targeted at understanding this often-misunderstood condition, these hospitals play an integral role in shaping future approaches leading towards enhanced care for those living with Tourettes worldwide

Which are the best cities for tourette syndrome clinical trials?

When it comes to tourette syndrome clinical trials, several cities are at the forefront of research and development. New Haven, Connecticut leads with 5 active trials exploring treatments like TSupport (a Traditional Chinese Medicine), Neurofeedback from the SMA, and T92. Nashville, Tennessee follows closely behind with 3 ongoing studies focused on interventions such as ecopipam and Ecopipam HCl. Gainesville, Florida also offers 3 active trials investigating options like Medtronic Percept Neurostimulator and medical cannabis. Lastly, Baltimore, Maryland contributes to advancements in care through studies on Habit Reversal Training and Medtronic Activa Deep Brain Stimulation System. Together with Boston's focus on Cognitive Behavioral Therapy (CBT) among other avenues of research, these cities provide individuals with tourette syndrome access to cutting-edge clinical trials that offer hope for improved management of their condition.

Which are the top treatments for tourette syndrome being explored in clinical trials?

In the realm of clinical trials for Tourette syndrome, two treatments are making waves. The Medtronic Percept Neurostimulator, a cutting-edge device, is currently being explored in one active trial dedicated to this condition. This innovative technology entered the scene in 2022 and shows great promise. Another contender is TSupport, an intriguing Traditional Chinese Medicine solution also undergoing testing in a single active trial specific to Tourette syndrome. With both treatments having recently emerged on the scene, researchers are eagerly awaiting further results that could potentially transform the lives of individuals affected by this neurological disorder.

What are the most recent clinical trials for tourette syndrome?

Recent clinical trials have brought hope to those affected by Tourette syndrome, with promising advancements in treatment. One notable trial involves the use of ecopipam at a dosage of 1.8 mg/kg/day, showing potential benefits for individuals with Tourette syndrome. Another study examines the effectiveness of SCI-110 as a possible therapeutic option during Phase 2 testing. While an earlier trial explored the use of medical cannabis for Tourette syndrome, further research is necessary to establish its efficacy conclusively. These ongoing investigations hold promise for improving the lives and managing symptoms in individuals living with this neurological condition.

What tourette syndrome clinical trials were recently completed?

In October 2019, Emalex Biosciences Inc. successfully completed a clinical trial investigating the efficacy of Ecopipam for the treatment of Tourette syndrome. This trial represents an important step in exploring potential therapies to alleviate symptoms associated with this neurological disorder. The completion of this study showcases ongoing efforts to improve outcomes and quality of life for individuals affected by Tourette syndrome.